Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Back in Black for Second Quarter

Affymetrix today reported net income of $5.2 million on revenues of $68.6 million for the second quarter ending June 30, compared to a loss of $1.6 million on revenues of $71 million for the second quarter 2002 and a turnaround from its first quarter net loss of $12.7 million on revenues of $67 million.


The company attributed the gains to record instrument revenue of $15.6 million on top of revenues of $30 million from sales of its GeneChip brand arrays. Wafer sales to Perlegen Sciences accounted for $2.8 million, compared to $5.6 million for the same period a year ago.


Affymetrix reported R&D expenses of $16.6 million for the quarter, compared to $17.3 million for the year-ago quarter.


The company reported cash and cash equivalents of $37 million on June 30, compared to $68 million on Dec. 31, 2002.


The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.